摘要
The unique characteristics of the deep space environment,microgravity,cosmic radiation,and extreme temperature fluctuations,are emerging as major driving forces for pharmaceutical innovation.These factors provide new avenues for optimizing drug formulations,improving crystal structure quality,and accelerating the discovery of therapeutic targets.Advances in deep space research not only help overcome critical bottlenecks in terrestrial drug development but also promote progress in structure-based drug design and deepen understanding of cellular stress-response mechanisms.Current progress in space-based pharmaceutical research primarily includes the study of disease mechanisms under microgravity,protein crystallization in microgravity,and drug development utilizing deep space radiation and resources.However,the operational complexity,high costs,and limited data reproducibility of space experiments remain key challenges hindering widespread application.Looking ahead,with the integration of automation,artificial intelligence analysis,and on-orbit manufacturing,deep space drug development is expected to achieve greater scalability and precision,opening a new frontier in biopharmaceutical science.
深空特有的微重力、宇宙辐射与极端环境,正逐渐成为推动药物创新的重要驱动力。这些独特因素为优化药物剂型、提升晶体结构质量及加速疾病治疗靶点的发现提供了新路径。深空研究的进展不仅有助于突破地面药物开发的关键瓶颈,还可推动基于结构的药物设计进展,加深人们对环境应激下细胞响应机制的理解。目前,深空药物开发的进展主要包括基于微重力探索疾病机制、基于微重力的蛋白质结晶及基于深空辐射和深空资源的药物开发。然而,实验条件受限、高昂成本及数据可重复性不足等问题是目前限制其广泛应用的关键挑战。未来,随着自动化技术、人工智能分析和在轨制造等新兴技术的融合应用,深空药物开发有望实现更高的规模化与精准化,从而开辟生物制药科学的新前沿。
出处
《中南大学学报(医学版)》
2025年第8期1371-1384,共14页
Journal of Central South University (Medical Science)
基金
supported by the National Natural Science Foundation of China(82272067).
